The cell type speci®city of the regulation of expression of the potent growth inhibitory cytokine transforming growth factor-beta (TGF-b), prompted our analyses of the regulation of TGF-b1 gene expression in glial cells by viral and cellular oncoproteins. We have shown that SV40 T-antigen diminished TGF-b1 expression in glial cells and this repression was dependent on the ability of T-antigen to interact with the tumor suppressor protein, pRb, and two structurally related proteins, p107 and p130. The cellular transcription factor E2F-1, which is a downstream eector of T-antigen, was unable to in¯uence expression from the TGF-b1 promoter by itself. Interestingly, E2F-1 could overcome viral Tantigen-mediated repression of the TGF-b1 promoter, suggesting potential feedback loop between TGF-b and E2F in virally transformed glial cells. Using deletion analyses, we have mapped two E2F-1-responsive regions on the TGF-b1 promoter: a T-antigen-dependent negative regulatory sequence (TdNRS) between 7323 and 7175, and a T-antigen-independent positive regulatory sequence (TiPRS) between 734 and +10 on the TGF-b1 promoter. Further examination of TiPRS revealed the presence of a functional E2F binding site. Interestingly, the amino terminus of E2F-1 was required for its activation of TGF-b1 expression, as mutations in that domain abolished the ability of E2F-1 to increase TGF-b1 expression. These data suggest that yetuncharacterized interaction between the amino terminus of E2F-1 and cellular proteins regulates TGF-b1 expression. The mechanism for E2F-1-mediated Tantigen-dependent regulation of TGF-b1 expression from TdNRS awaits further characterization.
Introduction
The potent pleiotropic cytokine, TGF-b, represents a family of structurally related isoforms that serve vital functions in development, physiology and immunity (reviewed by Benzakour, 1994; Kingsley, 1994; . Three characterized mammalian isoforms TGF-b1, TGF-b2 and TGF-b3 exhibit high individual conservation (498% identity) across species, but signi®cantly dier from each other (74 ± 78% identity). The various isoforms are generally functionally interchangeable in most biological assays , but appear to be distinct in their spatial and temporal expression, with regard to both developmental-stage and tissue-speci®city (Flanders et al., 1991; Wall and Hogan, 1994) .
TGF-b1 has been shown to dierentially modulate growth of various cell types, with stimulation of growth of mesenchymal cells but inhibition of growth of a wide variety of normal and transformed epithelial, endothelial, lymphoid and hematopoietic cells (reviewed in . These disparate functions of TGF-b1 are attributed at least in part to its ability to dierentially regulate selective inhibitors of cyclin-dependent kinases, including ink-4 or p15 and kip-1 or p27 (reviewed by Polyak et al., 1994; Sherr and Roberts, 1995) . The complex signal transduction cascade triggered by TGF-b appears to control the phosphorylation status of many cellular proteins, including the retinoblastoma gene product, pRb. Indeed, the hyperphosphorylated form of pRb is observed under conditions of TGF-b-mediated growth stimulation, while the hypophosphorylated form of pRb is predominant under conditions of growth inhibition (Polyak et al., 1994) . In turn, the phosphorylation status of pRb in¯uences its ability to interact with its viral and cellular partners, including the transcription factor E2F (reviewed by ; also see Chellapan et al., 1992) .
E2F has been postulated to be a critical regulator of coordinated S-phase gene expression (Johnson et al., 1993) . E2F DNA binding sites, with consensus sequence, 5' TTTSSCGC-3' (S=C or G), have been identi®ed in promoters for several cellular S-phase genes, including E2F-1 itself, c-myc dihydrofolate reductase (DHFR), cdc2, thymidine kinase (tk), cyclin D1, c-myb, ribonucleotide reductase, and DNA polymerase a (Dpola), and have been shown to functionally contribute to the transcriptional regulation of these promoters (for reviews, see . In fact, a minimal promoter element containing a single E2F-binding site in the DHFR promoter has been shown to be sucient for the proper temporal expression of the DHFR gene (Means et al., 1992; Slansky et al., 1993 ). E2F appears to be a multicomponent transcription factor with many identi®ed members of a growing family (reviewed in Ivey-Hoyle et al., 1993; LaThangue et al., 1994; Lees et al., 1993; Sardet et al., 1995) . Further, E2F transcriptional activity appears to be regulated by its interaction with various cellular proteins, including pRb, p107, cyclins A and E, and cyclin dependent kinases (cdk) (Chellapan et al., 1991; Helin et al., 1993; Hiebert et al., 1992; Weintraub et al., 1992) .
The modulation of the phosphorylation status of pRb by TGF-b1 implicated a downstream role for E2F-1. Indeed, E2F-1 has been shown to overcome the eect of TGF-b1 mediated growth inhibition (Schwarz et al., 1995) . However, the interrelationship between TGF-b and the oncoproteins of both viral and cellular origin is much more complex. Growth inhibition of keratinocytes mediated by TGF-b1 is abrogated by transforming proteins of DNA tumor viruses, including the papovaviral T-antigen, the papillomaviral E7 and the adenoviral E1A (Pietenpol et al., 1991) . The adenoviral transactivating protein E1A has also been demonstrated to repress the expression from the TGF-b promoter (Datta and Bagchi, 1994) . Further, the overexpression of pRb has been shown to activate TGF-b gene expression (Kim et al., 1992; ). There appears to be an intriguing cell-type speci®c component to the regulation of the TGF-b promoter by the viral and cellular oncoproteins (Datta and Bagchi, 1994; Kim et al., 1992; Roberts et al., 1991) .
In this report, we examined the regulation of TGF-b gene expression in glial cells by the viral and cellular oncoproteins. We demonstrated that, like its adenoviral counterpart, the papovaviral T-antigen repressed the expression of TGF-b1. Further, pRb is able to mediate a similar repression of the TGF-b1 promoter in glial cells. By itself, E2F-1 is unable to in¯uence transcription from the TGF-b1 promoter, but interestingly, can overcome the repression mediated by viral T-antigen, but not the repression by pRb. E2F-1 appears to regulate TGF-b1 expression via a T-antigen-dependent negative regulatory sequence (TdNRS) and a Tantigen-independent positive regulatory sequence (TiPRS) located adjacent to the P1 transcriptional initiation site within the TGF-b1 promoter. Further, E2F-1 is able to activate transcription from a minimal promoter construct containing TiPRS in the absence of T-antigen. The requirement of the T-antigen in E2F-1 mediated transactivation of the full length promoter may re¯ect the ability of the viral protein to both repress the basal activity of TGF-b1 as well as its ability to interact with speci®c cellular partners for E2F-1. Based on these data, a model is proposed for a complex feedback loop between TGF-b and E2F in both normal and transformed cells.
Results

Regulation of TGF-b1 expression by viral and cellular oncoproteins in glial cells
Reporter constructs containing the full length TGF-b1 promoter cloned upstream of the CAT reporter gene were transiently transfected into the U-87MG glioblastoma cell line in the absence and presence of viral and cellular oncoproteins. The papovaviral SV40 Tantigen strongly repressed expression from the TGF-b1 promoter (Figure 1 , compare lane 3 to lane 1). Tantigen-mediated repression of TGF-b1 expression was dependent on its interactions with the pocket proteins, as evidenced by the inability of a T-antigen pocket protein-binding mutant T k1 (Quartin et al., 1994) to aect the expression of TGF-b1 (Figure 1 , compare lane 4 to lane 1). Other T-antigen mutants, including those defective for binding to p53, were able to mediate repression of TGF-b1 expression (data not shown). These data are in agreement with prior observations indicating that viral oncoproteins, including E1A, can diminish expression from the TGF-b1 promoter (Datta and Bagchi, 1994) .
The cellular tumor suppressor retinoblastoma gene product, pRb, itself weakly attenuated expression from the TGF-b1 promoter in glial cells (Figure 1 , compare lane 2 to lane 1). These data corroborate with previous observations in other cell lines that have demonstrated the regulation of TGF-b gene expression by the Rb gene product (Kim et al., 1992) . Other Rb-family members, p107 and p130 were unable to signi®cantly aect the level of expression from the TGF-b1 promoter in glial cells (data not shown).
The cellular oncogene E2F-1 did not signi®cantly aect the expression from the TGF-b1 promoter over a wide variety of concentrations, as exempli®ed ( Figure  1 , compare lane 5 to lane 1). Interestingly, E2F-1 appeared to overcome T-antigen-mediated-repression of TGF-b1 expression (Figure 1 , compare lane 7 to lanes 3 and 1). Further, E2F-1 was unable to overcome Rb-mediated repression of the TGF-b1 promoter (Figure 1 , compare lane 6 to lanes 2 and 1). These data suggested that the ability of E2F-1 to overcome T-antigen mediated repression of TGF-b1 expression was independent of the interaction of E2F-1 with Rb. These observations are further correlated by analyses with mutants of E2F-1 (unpublished observations, also see Figure 7 ). Further, we have previously demonstrated that similar concentrations of E2F-1 could activate transcription from E2F-dependent reporter constructs in the U-87MG cell line (Raj et al., 1996) . Additional analyses indicated that E2F-1 was unable to signi®cantly modulate the expression from either TGFb2 or TGF-b3 promoters (data not shown). These data were not surprising, given the dissimilitude between the promoters of the dierent isoforms and indicated that the regulation of TGF-b by E2F-1 was restricted to the TGF-b1 isoform.
Regulation of TGF-b1 expression by E2F-1 requires Tantigen
In order to further examine the requirement for Tantigen in the E2F-1-mediated regulation of TGF-b1 expression, a glial cell line, N20.1, stably transformed with a temperature-sensitive SV40 T-antigen was utilized (Verity et al., 1993) . High levels of the viral T-antigen were expressed in N20.1 cells only at permissive temperature (348C), but not at nonpermissive temperature (398C) (Verity et al., 1993) . Under similar conditions, the Tk1 mutant, defective in its ability to bind pocket-domain proteins was unable to promulgate conditions for E2F-1 activity (data not shown). Taken together, these data con®rm the requirement for SV40 T-antigen in the E2F-1 mediated regulation of TGF-b1 gene expression.
E2F-1 regulates the endogenous TGF-b1 RNA level in the presence of T-antigen
The eect of E2F-1 on the endogenous TGF-b1 level was examined by Northern blot analyses. N20.1 glial cells, under conditions permissive for viral T-antigen expression, were infected with an adenovirus expressing the E2F-1 gene (Schwarz et al., 1995) . E2F-1 modestly (2.5 ± 3-fold) increased the expression of TGF-b1 message in the infected glial cells ( Figure  3a and b, compare lane 3 to lane 2). The foldincrease in E2F-1 levels under the same conditions was more dramatic perhaps due to the autoinduction of E2F-1 (Johnson et al., 1994) (Figure 3c , compare lane 3 to lane 2). As a control for RNA loading, the levels of b-actin message were analysed. The results con®rmed equal loading ( Figure 3d ). A similar experiment performed in N20.1 cells under nonpermissive conditions, did not show any increase in TGF-b1 expression (data not shown). The lack of increase under non-permissive conditions may be secondary to the slower kinetics of cellular growth and replication. We have noticed the appearance of a faster migrating band (shown by an asterisk) in lanes corresponding to RNAs from N20.1 cells overproducing E2F-1 under permissive conditions. This observation suggests that E2F-1 induces expression of a cellular gene which shares some homology to TGFb1. Studies are in progress to further identify the gene corresponding to this RNA.
Identi®cation of the E2F-1-responsive region on the TGF-b1 promoter
Serial deletion analyses were performed in order to de®ne the minimal regions on the TGF-b1 promoter responsible for the E2F-1 mediated activation. The organizational structure of the TGF-b1 promoter constructs with the various enhancer elements is depicted ( Figure 4a ). As described earlier, the expression from the full length (phTG2) construct is enhanced by the presence of E2F-1 in N20.1 cells under conditions permissive for T-antigen expression (Figure 2 , lanes 1 and 2). Most of the 5'¯anking promoter sequences could be deleted without a loss of activation by E2F-1, as seen with the phTG5 and phTG6 constructs ( Figure  4b, lanes 1 through 4) . Further deletions of the TGF-b1 promoter removing both the previously identi®ed Rbcontrol element (phTG 7.1), or the E1A-responsive region (phTG 7.2) did not aect the responsiveness to E2F-1 (Figure 4b , lanes 5 through 10). Expression from a minimal construct, phTG 7.4.3, which lacks the Rbresponsive element and the E1A-responsive element, is enhanced by E2F-1 (Figure 4b , compare lane 16 to lane 15). Expression from the basal pCAT promoter was not aected by E2F-1 (data not shown). Taken together, these data indicate that a positive E2F-1-responsiveregion is present in sequences spanning 734 to +10 on the TGF-b1 promoter.
Interestingly, when similar deletion analyses were performed in N20.1 cells under non-permissive conditions, the phTG5 and six constructs showed minimal responsiveness to E2F-1 (Figure 4c , lanes 1 ± 4). However, the phTG7 construct and subsequent deletions were signi®cantly activated by E2F-1 in the absence of T-antigen. These data implicate the presence of upstream T-antigen-dependent-negativeresponsive-sequences (TdNRS), important for E2F-1 mediated activation of the TGF-b1 promoter and corresponding to sequences between 7323 and 7175 on the TGF-b1 promoter (Figure 4c , lanes 5 ± 10). The smallest deletion construct, phTG 7.4.3, is also activated by E2F-1 under these conditions, confirming the presence of an independently-positiveresponsive-sequence (TiPRS) between sequences corresponding to 734 to +10 on the TGF-b1 promoter. A similar panel of responsiveness was observed in the U-87MG cell line under conditions lacking the viral Tantigen ( Figure 4d ) and in the presence of transiently transfected T-antigen (data not shown). Taken together, these data implicated the presence of two E2F-1-responsive regions on the TGF-b1 promoter, the upstream TdNRS which is dependent on the presence of T-antigen for transactivation by E2F-1 and the downstream TiPRS, which is transactivated by E2F-1 independent of T-antigen. In the absence of T-antigen, TdNRS acts as a negative regulatory element and eclipses the activity from TiPRS, accounting for the inability of E2F-1 to enhance the expression from the full length TGF-b1 promoter. In the presence of T-antigen, the in¯uence of TdNRS is removed and E2F-1 is able to activate TGF-b1 expression via TiPRS. Initial computer-aided analyses have shown no clear binding sites or responsive Figure 2 E2F-1 regulation of TGF-b1 expression requires T-antigen. Two mg of the phTG2 reporter construct was transiently transfected into the N20.1 glial cells in the absence (lanes 1, 3, and 5) and in the presence (lanes 2, 4, and 6) of 10 mg of an E2F-1 expression plasmid. The eect was examined at 348C (permissive temperature for T-antigen expression) (lanes 1 and 2), at 398C (non-permissive temperature for T-antigen expression) (lanes 3 and 4), and at 398C (non-permissive temperature) in the presence of 10 mg of co-transfected T-antigen expressor plasmid (lanes 5 and 6). A representative experiment is shown, with numbers depicting the percentage acetylation Figure 4 Identi®cation of the E2F-1-responsive region on the TGF-b1 promoter. The schematic depicts the architecture of the TGF-b1 transcriptional control region, with known transcription factor binding sites and the various deletion constructs which were used in these studies. The blueprint depicts the organizational structure of the various TGF-b1 promoter constructs, with the binding sites for the known transcription factors (a). The composition of these promoter reporter constructs has been previously reported (Kim et al., 1989) . Representative experiments extolling the eect of 2.5 mg of the E2F-1 expression plasmid on 3 mg of each reporter construct in N20.1 cells at 348C (b), N20.1 cells at 398C (c) and in U-87MG cells (d) are depicted Regulation of TGF-b1 transcription by E2F1 P Thatikunta et al elements within the TdNRS. Further studies are underway to clearly de®ne speci®c sequences within TdNRS that are responsible for this interplay between T-antigen and E2F-1. The identity of the TiPRS and the regulation of TGF-b gene expression from this site has been further examined.
Interplay between viral and cellular oncoproteins regulates TGF-b1 expression
The proximity of Rb-, E1A-and E2F-(TiPRS) responsive elements within the TGF-b1 promoter prompted analyses of the potential interaction between these factors in the absence and presence of their binding sites on the promoter. Expression from a TGF-b1 reporter construct containing all three sites (phTG 7.0) was diminished by the addition of both Rb-and T-antigen (but not Tk1), and enhanced by E2F-1 (Figure 5 ). Unlike T-antigen, Rb was also able to decrease the expression of phTG 7.0 in the presence of E2F-1. Removal of the Rbresponsive element (phTG 7.2 and phTG 7.4) abolished the ability of Rb to decrease the basal transcriptional activity but did not aect its repression of the E2F-1 enhanced transcription ( Figure 5 ). Removal of the T-antigen-responsive site (phTG 7.4.3) abolished the ability of T-antigen to diminish the basal expression. E2F-1 was able to signi®cantly enhance the expression from these constructs containing TiPRS (Figure 5 ), but not from the basal reporter construct, pCAT (data not shown). The ability of E2F-1 to activate a minimal TGF-b1 promoter can be overcome by pRb, but not by the viral T-antigen ( Figure 5 ). These ®ndings were not surprising, given the known ability of pRb but not T-antigen to squelch the functional activity of E2F-1. Taken together, these data con®rm the previous identification of Rb-and E1A/ T-antigen-responsive sites on TGF-b1 promoter and the distinct identity of the E2F-1 responsive element on the TGF-b1 promoter. A complex interplay between these cellular and viral proteins and their responsive sites on the promoter is evident.
E2F-1 binds to the TiPRS on the TGF-b1 promoter
Like other well-characterized transcription factors, E2F-1 has been shown to regulate gene expression due to its ability to directly interact with the cellular promoters. Computer-aided analyses of TiPRS indicated the presence of a potential E2F-binding site, with the nucleotide sequence 5'-TTCGCGG-3'. The ability of E2F-1 to bind TiPRS was initially examined with puri®ed bacterially-expressed recombinant GST-E2F-1. The full length recombinant E2F-1 protein binds to a radiolabeled TiPRS probe under standard mobility shift assay conditions ( Figure 6a , lanes 2 ± 4). Truncated E2F-1 proteins like the amino terminus deleted E2F-1DN (88 ± 437) ( Figure 6a , lanes 5 ± 7), Figure 5 E2F-1 activation of the minimal TGF-b1 promoter is overcome by Rb. Two mg of the indicated TGF-b1 reporter constructs were transiently transfected into the U-87MG glial cells, in the absence and presence of 10 mg of cytomegalovirus promoter-driven expression plasmids for the indicated genes. The numbers indicating the activity was normalized to a basal of 100. These numbers were derived from the percentage of chloramphenicol acetylation in each sample 1 2 3 4 5 6 7 8 9 10 1 2 3 4 5 6 7 8 9 10 _ _ E2F-1 (1-437) E2F-1 (88-437) Gst E2F-1 (1-437) E2F-1 (88-437) Gst a b Figure 6 E2F-1 binds to its responsive region on the TGF-b1 promoter. Increasing concentrations of puri®ed bacterially-produced recombinant GST-E2F-1 proteins (Logan et al., 1994; Krek et al., 1995) were examined for binding to the responsive region on the TGF-b1 promoter (a, lanes 2 ± 7) and to the consensus E2F-binding site on the DHFR promoter (b, lanes 2 ± 7). E2F-1 (1 ± 437) represents the full length version of the protein and the mutant E2F-1DN contains amino acids 88 ± 437. The control experiments with GST protein alone are also shown (a and b, lanes 8 ± 10) and the DNA-binding domain E2F-1DNDC (88 ± 241) (data not shown) bind to TiPRS. Neither the GST protein ( Figure 6a , lanes 8 ± 10) nor a bindingdefective mutant E2F-1D-(88 ± 187) (data not shown) form complexes with the TiPRS. Further, the cellular partner for E2F-1, DP-1, does not itself bind, but dramatically enhances the binding of E2F-1 to TiPRS (unpublished observations). A similar pro®le of protein-DNA interactions was seen for the consensus E2F site from the well characterized dihydrofolate reductase promoter (Figure 6b , lanes 2 ± 10). These data strongly suggest that E2F-1 binds to the TiPRS on the TGF-b1 promoter. Methylation interference assays have demonstrated an interaction between the recombinant E2F-1 protein and speci®c guanine residues on TiPRS (Figure 7a ). The E2F-1-protected nucleotides lie within the computerpredicted E2F-binding site, 5'-TTCGCGG-3' (protected nucleotides underlined) (Figure 7b ). Further confirmation of the speci®city of E2F-1 binding to TiPRS was derived from competition gel shift analyses (Figure 7c ). DNA-protein complexes between the recombinant E2F-1 protein and the DHFR E2F probe were eciently completed by the addition of increasing concentrations of cold TiPRS oligonucleotides (Figure 7c , compare lanes 2 ± 4 to lane 1) or cold DHFR oligonucleotides (Figure 7c , compare lanes 8 ± 10 to lane 1). In contrast, mutant TiPRS oligonucleotides with substitution of the protected nucleotides (GCG to AGA) were unable to eciently compete the formation of the E2F DNAprotein complexes (Figure 7c , compare lanes 5 ± 7 to lane 1). Cumulatively, these data strongly indicate that E2F-1 binds TiPRS on the TGF-b1 promoter speci®cally and in a manner similar to the complexes seen with the DHFR E2F site.
The N-terminus of E2F-1 is required for activation of TGF-b1 expression
In order to examine the relationship between the ability of E2F-1 to bind TiPRS and its ability to transactivate TGF-b1 expression, the minimal TGF-b1 promoter construct with mutations in the E2F-binding site within TiPRS was constructed (phTG 7.4 m). Unexpectedly, we observed that E2F-1 was still able to signi®cantly transactivate expression from the mutated promoter construct (Figure 8, phTG 7.4 m) . These data suggested that the ability of E2F-1 to transactivate TGF-b1 expression did not require direct binding to TiPRS.
Further con®rmation of the ability of E2F-1 to enhance expression from the minimal TGF-b1 reporter construct was obtained by utilization of mutant versions of E2F-1 to delineate the domains of E2F-1 involved in this transcriptional activation. An amino terminal deletion mutant of E2F-1 (E2F-1DN), which E2F-1 binds speci®cally to its responsive region on the TGF-b1 promoter. Methylation interference assays were performed to identify the speci®c nucleotide residues within TiPRS on the TGF-b1 promoter that are involved in the interaction of E2F-1 with DNA (a). The protected residues are marked by the arrows. The sequence of TiPRS is detailed, with the bold-face type highlighting a potential E2F-binding site and the arrows denoting the protected nucleotides (b). Competition gel shift analyses were then performed with increasing concentrations of wild type and mutant TiPRS and DHFR E2F oligonucleotides to examine the ability of these competitors to diminish the formation of E2F-1 protein-DNA complex with the DHFR E2F probe (c) is still capable of interaction with pRb, binding DNA and enhancing expression from E2F-dependent promoters (see Figure 6a , lanes 5 ± 7, and Figure 8 control p3E2F-CAT), was unable to mediate the enhanced transcriptional activity from the minimal TGF-b promoter (see phTG 7.4 or phTG 7.4 m in Figure 8 ). These data suggest that the amino terminus of E2F-1 protein plays a role in E2F-1-mediated transcriptional activation of TGF-b1. The amino terminus of E2F-1 is extremely hydrophobic, with a high concentration of prolines and represents an excellent site of interaction with cellular factors including cyclin A. Another mutant version of E2F-1, E2F-1D24 with a small deletion blocking its interaction with cyclin A, was still able to enhance expression from the TGF-b1 promoter (Figure 8 ). These data implicate novel protein-protein interactions between unidenti®ed cellular proteins that interact with the amino terminus of E2F-1 that may play a role in the regulation of E2F-1-dependent TGFb1 expression.
Discussion
The transforming ability of the papovaviral T-antigen has been extensively documented (reviewed in Manfredi and Prives, 1994) . T-antigen can immortalize but cannot alone fully transform cells (reviewed in Bryan and Reddel, 1994) . T-antigen overcomes the restriction at the G 1 /S checkpoint and drives the cells into Sphase. The E2F binding sites in the promoters of Sphase speci®c genes have been demonstrated to play a critical role in the proper temporal expression of these genes (Means et al., 1992; Neuman et al., 1994; Slansky et al., 1993) . Previous studies indicate that T-antigen sequesters pRb, freeing E2F to bind to the responsive sites and regulate the expression of the S-phase genes (reviewed in Nevins, 1992) .
In this report, we demonstrated that the viral Tantigen was able to repress the expression of the negative growth regulator, TGF-b1 in glial cells. The decreased expression level of TGF-b1 may contribute to the oncogenicity of the viral protein. These data supported previous observations demonstrating a similar repressive role for the adenoviral E1A oncoprotein (Datta and Bagchi, 1994) . Mutational analyses indicated that the repression mediated by the viral T-antigen required interaction with the members of the pRb family. Again, these data were in concordance with the requirement of similar regions on the adenoviral E1A protein (Datta and Bagchi, 1994) . The ability of the cellular oncoprotein, pRb, to repress transcription from the TGF-b1 promoter in glial cells con®rmed previous indications of cell-type speci®city . Since pRb and T-antigen both have similar eects on TGF-b expression in glial cells, T-antigen-mediated repression of the TGF-b1 promoter may involve interactions with members of the Rb family other than pRb.
Overexpression of E2F-1 was unable to signi®cantly aect TGF-b1 promoter activity in glial cells in the absence of the viral T-antigen. However, E2F-1 dramatically activated expression of the TGF-b1 promoter in the same glial cells in the presence of SV40 T-antigen. We have demonstrated that the level of the endogenous TGF-b1 mRNA was enhanced by E2F-1. These changes may be indicative of¯uctuations in the level of expression of TGF-b1 during cell-cycle in transformed cells.
The ability of E2F-1 to activate transcription from the TGF-b1 promoter appears to be a function of its ability to bind to its responsive region adjacent to the transcription initiation site of the TGF-b1 P1 promoter. In fact, E2F-1 regulates the expression from a minimal promoter construct containing its responsive site (TiPRS), even in the absence of Tantigen. However, T-antigen is required for E2F-1-mediated transactivation of longer TGF-b1 promoter constructs. These data indicate that T-antigen may function to remove negative in¯uences mediated at TdNRS and allow the unencumbered regulation of TGF-b1 by E2F-1.
Analysis of TiPRS indicated the presence of a functional E2F-binding site. The E2F binding site within TiPRS was similar to the classic E2F-binding site on the DHFR promoter and displayed similar binding characteristics. However, unlike the DHFR promoter, the binding of E2F-1 to TiPRS was not sucient for E2F-1-mediated regulation of the TGF-b1 promoter. Expression from a reporter construct with the E2F-1 binding site within TiPRS mutated, was still enhanced by the addition of E2F-1. Further, an E2F-1 mutant capable of binding DNA and with an intact transactivational domain, was unable to increase TiPRS-driven transcription. These data indicated that while the DNA-binding ability of E2F-1 may play no role in the regulation of TGF-b1 expression, the amino terminus of E2F-1 is necessary for this function. This function may be indicative of the protein ± protein interactions that have been shown to occur within this domain. An untested candidate for these protein± protein interactions is Sp-1 and further analysis is being carried to examine if Sp-1 is involved in the regulation of TGF-b1 gene expression via TiPRS.
These data have also indicated that T-antigen and E1A repressed the transcription of TGF-b through the GC region located between 791 and 782 on the TGF-b1 promoter (data shown here; Datta and Bagchi, 1994) . pRb may mediate its repression through previously identi®ed responsive regions which map to 7148 and 7158 and between 7165 and 7175 on the TGF-b1 promoter . E2F-1 appears to activate TGF-b1 promoter, via a newly identi®ed binding site, located between 734 and +10 on the TGF-b1 promoter. The repression of TGF-b expression mediated by pRb may be a function of both Figure 8 The N-terminus of E2F-1 is required for activation of TGF-b1 expression. Two mg of the phTG2 reporter construct containing the full length TGF-b1 promoter cloned upstream of the CAT reporter gene were transiently transfected into the U-87MG glial cells in the absence or presence of 10 mg of expression plasmids bearing truncated versions of E2F-1 downstream of a cytomegalovirus promoter. The numbers indicate transcription activity of each sample and normalized to a basal of 100. These values were determined based on the percentage of acetylation of chloramphenicol its direct eect on the Rb-responsive region, as well as its ability to sequester E2F-1 from interaction with the E2F-1 binding site. The repression mediated by Tantigen may be attributed to its interaction with the GC-rich region, as well as its ability to modulate expression from both the Rb-responsive region and TdNRS. Further, the inability of E2F to signi®cantly aect the expression of the full length TGF-b1 promoter may be due to the presence of attenuating in¯uences in the full length promoter, such as the Tantigen responsive GC site, the Rb-responsive element, as well as the uncharacterized TdNRS.
Taken together, these data support a model for the cross-regulation of TGF-b1 and E2F (Figure 9 ). TGF-b1 activates a signal transduction cascade, resulting in the elevated levels of activated inhibitors of cyclin-dependent kinases, p27 and p15. These phosphoproteins functionally inactivate complexes of cyclins and cyclin dependent kinases (cdks), preventing their ability to phosphorylate pRb. The underphosphorylated form of pRb remains in a complex with E2F, while phosphorylation of pRb triggers the release of free E2F. Free E2F, which is a transcriptionally active species, can regulate the expression of several Sphase genes, including DHFR, cdc-2, tk and others previously mentioned. Free E2F can also overcome Tantigen mediated repression of the TGF-b1 promoter, and may itself under certain conditions have an unimpeded or direct eect on TGF-b1 promoter (depicted as a dotted line). Since TGF-b1 can cause both the hypo-and hyper-phosphorylation of pRb, the overall eect of TGF-b1 on E2F is depicted as both positive and negative.
These ®ndings implicate a functional role for E2F-1 in the regulation of TGF-b1 gene expression and point to an intricate web of controls that regulate TGF-b1 gene expression. The delicate interplay between the viral and the cellular oncoproteins dictates the level of expression of TGF-b1. The ability of TGF-b1 to act in both an autocrine and in a paracrine fashion may confer a selective growth advantage to the transformed cell.
Materials and methods
Cell lines
U-87MG cell line is a human astrocytic cell line derived from a glioblastoma, while N20.1 represents a mouse oligodendroglial cell line derived by transformation with a temperature sensitive SV40 T-antigen.
Plasmids
The expression pCMV-E2F-1, pCMV Rb, and pCMV p107 constructs were previously described ) and were obtained from Dr Arturo Sala (Sala et al., 1994) . The pCMV SV40T, pCMV SV40T k1 , and the pCMV SV40T p4 constructs (Quartin et al., 1994; Tevethia et al., 1988) were a kind gift of Dr Judith Campisi. phTG 2 (71132 to +11), phTG 5 (7453 to +11), phTG 6 (7323 to +11), phTG7 (7175 to +11), phTG 7.1 (7160 to +11), phTG 7.2 (7100 to +11), phTG 7.3 (771 to +11), phTG 7.4 (760 to +11), and phTG 7.4.3 (734 to +11) are a series of deletion constructs of the 5'-promoter region of the human TGF-b1 gene (kindly provided by Dr Seong Jin Kim, NCI), and are structurally depicted in Figure 4a . All constructs were veri®ed by sequencing, and prepared using commercial kits (Qiagen).
Transfection and reporter gene assays
Transient transfection assays in the U-87MG cell line were carried out by a modi®cation of the calcium phosphate method, as previously described (Raj and Khalili, 1994) . In order to maximize transfection eciency in the N20.1 cells, the calcium phosphate precipitates were allowed to sit on Figure 9 Model for cross-regulation between TGF-b and E2F. The eect of TGF-b1 on the phosphorylation status of Rb via regulation of the inhibitors of cyclin-dependent kinases, p27 and p15, cyclins and cyclin dependent kinases (cdks) is depicted on the right half of the panel. Free E2F, released by either phosphorylation of pRb, or by sequestration of pRb by the viral T-antigen can regulate the expression of several S-phase genes and overcome T-antigen mediated repression of the TGF-b1 promoter the cells for 6 h, and were washed o without a glycerol shock. Experiments were designed to be promoter controlled, with pCDNA3 (pCMV) added to equalize the total amounts of promoter in each reaction mixture. Each experiment was repeated four or more times with dierent plasmid preparations. Forty-eight hours post-transfection, cellular extracts were prepared by freezing and thawing, and were subjected to CAT analysis as previously described (Raj and Khalili, 1994) .
DNA-protein interactions
Oligonucleotides were prepared commercially by Oligos Etc., Guildford, CT. Nuclear extract preparation and mobility shift assays were performed essentially as previously described (Raj and Khalili, 1994) . Brie¯y, 100 000 c.p.m. of end labeled probes were incubated at 48C for 30 min with 5 mg of nuclear extracts in a binding buer containing 1 mg poly [dI-dC], 5 mM dGTP, 12 mM HEPES (pH 7.9), 4 mM Tris (pH 7.5), 60 mM KCl, 5 mM MgCl 2 and 0.8 mM DTT. The complexes were resolved on a low-ionic strength (0.56Tris-borate EDTA (TBE) 4% native polyacrylamide gel. For the competition experiments, the extracts were preincubated at 48C with the unlabeled competitor oligonucleotide for 10 min, before the addition of probe, unless otherwise indicated.
Flow cytometric analysis
Semicon¯uent (60%) monolayers of N20.1 cells were blocked in G 1 /S by a double thymidine block. Basically, the cells were treated with media containing thymidine (conc=200 nM) for 16 h, washed with PBS, released in normal media for 9 h and then treated with media containing thymidine for another 16 h. Cells were ®xed in 70% ethanol and cellular DNA content was assayed by the propidium iodide staining. FACS analysis was performed in a Coulter Pro®le II instrument with software program Multicycle (Phoenix Flow Systems).
RNA analyses
Infection, RNA collection, and Northern blot analyses of the infected cells were performed essentially as described .
